Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes

Stock Information for Incannex Healthcare Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Incannex Healthcare Inc.

Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Incannex Announces Reverse Stock Split
Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board
Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program
Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards
Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.